Intelligent plasma cell disease health screening comprehensive system and dynamic hierarchical management method

Abstract

The present invention relates to the field of plasma cell disease, and specifically to an intelligent plasma cell disease comprehensive health screening system and a dynamic hierarchical management method. The method provided by the present invention includes: S101 obtaining medical information data; S102 dividing the dynamic management level of the subject into level one, level two, level three or level four; S103 judging whether the number of effective indicators is qualified; S104 analyzing whether there is a conflicting indicator combination; S105 analyzing whether the medical information data is complete for the first classification; S106 analyzing the acceptability of the medical information data; S107 generating inspection priority prompt information. The present invention can "low-threshold" include a wider range of target subjects into the dynamic management scope of the present invention, and carry out clear dynamic management grading and hierarchical comprehensive management methods, which is suitable for application scenarios such as big health screening.

Description

Technical Field

[0001] The present invention relates to the field of plasma cell disease, and in particular to an intelligent plasma cell disease health screening comprehensive system and a dynamic hierarchical management method. Background Art

[0002] Plasma cell disease refers to a group of malignant (for example, multiple myeloma is the most common plasma cell tumor) and non-malignant diseases in which the abnormal proliferation of plasma cells is accompanied or not accompanied by the production of a large number of abnormal antibodies. Plasma cell disease is a complex heterogeneous disease, and its occurrence and development have a certain process and stage. At different stages of the disease, plasma cells will show different characteristics in morphology, genetics, immunology and molecular biology. In other words, the current diagnosis and treatment of plasma cell disease requires the results of different types of examinations. However, due to the constraints of factors such as the personal experience of doctors and actual medical conditions, patients who visit primary medical institutions often find it difficult to get an accurate diagnosis of plasma cell disease. Therefore, it is necessary to develop a management system for plasma cell disease that is suitable for popularization in primary medical institutions.

[0003] Chinese patent application CN112562810A discloses a plasma cell tumor disease management and entry system, which mainly manages the patient's treatment information and efficacy information, intuitively obtains the treatment plan and treatment effect adopted by the patient during treatment, and provides data reference for the later treatment plan. Chinese patent application CN114067998A discloses a lymphoma clinical decision-making, teaching, and scientific research auxiliary support system, which mainly screens, diagnoses, treats, and monitors and follows up lymphoma patients by combining real-world clinical pathways and standard clinical pathways. The above-mentioned prior art relies more on obtaining accurate medical information from the hospital information system. However, due to the privacy of medical information, it is difficult for conventional systems to directly use the data recorded by the hospital information system. In addition, the above-mentioned prior art has a high threshold for the medical information of the subject (especially the examination result information), which is difficult to be actually applied in primary medical institutions or large-scale screening. Summary of the invention

[0004] In a first aspect, the present invention provides an intelligent plasma cell disease health screening and dynamic stratified management method, characterized in that it comprises the following steps:

[0005] S101 Obtaining medical information data of a subject, the medical information data including first data and second data; the first data including plasma cell ratio data and / or clinically relevant data, the clinically relevant data including blood calcium level, bone pain, anemia and urine protein level; the second data including examination result data; the examination including one or more of blood examination, urine examination, bone marrow examination, imaging examination, nuclear medicine examination, genetic examination and immunological examination;

[0006] S102, based on the first data, using a first dynamic classification mechanism, classifying the dynamic management level of the subject into level one, level two, level three or level four; if the dynamic management level of the subject is level one, proceeding to S103;

[0007] S103: using the first classification mechanism to determine whether the number of valid indicators of the second data is qualified; if so, proceed to S104; if not, proceed to S106;

[0008] S104: Analyze whether there is a conflicting indicator combination in the medical information data; if so, perform a first correction to exclude the conflicting indicator combination in the medical information data, generate the first corrected medical information data and enter S105; if not, directly enter S105;

[0009] S105: analyzing whether the medical information data is complete for the first classification; if so, generating a first classification result of the subject's plasma cell disease and a recommended first treatment plan, maintaining the subject's dynamic management level at level one and proceeding to S108; if not, proceeding to S106;

[0010] S106: Analyze the acceptability of the medical information data; if it is unacceptable, directly enter S107; if it is acceptable, perform a second correction on it and generate second corrected medical information data, and determine whether the index after the second correction is excluded in S104; if so, enter S107; if not, return to S105;

[0011] S107 generates inspection priority prompt information and determines whether the subject has newly entered medical data information; if so, returns to S104; if not, maintains the dynamic management level of the subject at level one and performs second comprehensive management;

[0012] The second comprehensive management method includes: having medical experts provide classification results and recommended treatment plans for the subject based on the medical information data, and tracking the actual diagnosis results and treatment plans actually accepted by the subject.

[0013] In some embodiments, S102 includes:

[0014] S11: Determine whether the first data satisfies a second dynamic classification mechanism; if yes, proceed to S12; if no, proceed to S13; wherein the second dynamic classification mechanism requires that the first data satisfies a preset data type for distinguishing plasma cell diseases;

[0015] S12: determining whether the preset data type for distinguishing plasma cell disease in the first data is abnormal; if so, classifying the dynamic management level of the subject into level one and proceeding to S103; if not, classifying the dynamic management level of the subject into level four;

[0016] S13: Determine the number of abnormal indicators in the clinical-related data; when the number of the abnormal indicators is at least three, classify the dynamic management level of the subject into level one; when the number of the abnormal indicators is two, classify the dynamic management level of the subject into level two; when the number of the abnormal indicators of the subject is at most one, classify the dynamic management level of the subject into level three and proceed to S14;

[0017] S14: determining whether the abnormal indicator of the subject is the urine protein level; if so, upgrading the dynamic management level of the subject to level 2; if not, proceeding to S15;

[0018] S15: Generate inspection priority prompt information and determine whether the subject has newly entered first data; if so, proceed to S16; if not, maintain the dynamic management level of the subject at level three;

[0019] S16: Determine whether the newly entered first data contains data information that has excluded other diseases; if so, upgrade the dynamic management level of the subject to level two; if not, maintain the dynamic management level of the subject at level three.

[0020] In some embodiments, the method further comprises:

[0021] S108: using the second classification mechanism, analyzing whether the medical information data is complete for the second classification; if so, generating a second classification result of the subject's plasma cell disease and a recommended second treatment plan, maintaining the subject's dynamic management level at level one and performing the first comprehensive management; if not, proceeding to S109;

[0022] S109 Generate inspection priority prompt information and determine whether the subject has newly entered medical data information; if so, return to S108; if not, maintain the dynamic management level of the subject at level one and perform second comprehensive management.

[0023] In some embodiments, the first integrated management method comprises: obtaining the actual diagnosis result of the subject and comparing the first classification result and the second classification result of the subject with the actual diagnosis result; and / or

[0024] Obtaining the treatment regimen actually received by the subject and its efficacy and comparing it with the recommended second treatment regimen;

[0025] When the comparison results are consistent, the first comprehensive management is maintained; when the comparison results are inconsistent, the subject is subjected to the second comprehensive management.

[0026] In some embodiments, if the dynamic management level of the subject is level 2, the following steps are performed:

[0027] S201: using the first classification mechanism, analyzing whether the medical information data is complete for the first classification; if so, upgrading the dynamic management level of the subject to level one and proceeding to S105; if not, proceeding to S202;

[0028] S202 Generate inspection priority prompt information and determine whether the subject has newly entered medical data information; if so, return to S201; if not, maintain the dynamic management level of the subject at level two and perform level three comprehensive management.

[0029] In some embodiments, if the dynamic management level of the subject is level three, the following steps are performed:

[0030] S301: using the first classification mechanism, analyzing whether the medical information data is complete for the first classification; if so, upgrading the dynamic management level of the subject to level one and proceeding to S105; if not, proceeding to S302;

[0031] S302 Generate inspection priority prompt information and determine whether the subject has newly entered medical data information; if so, return to S301; if not, maintain the dynamic management level of the subject at level three and perform the third comprehensive management.

[0032] In some embodiments, the third comprehensive management method includes monitoring the development trend of the subject's plasma cell disease; if there is a worsening development trend, upgrading the subject's dynamic management level; if there is no worsening development trend, maintaining the subject's dynamic management level at the original level.

[0033] In some embodiments, the method for analyzing the development trend of the plasma cell disorder of the subject comprises: determining whether the first data and / or the second data produce an abnormal trend, and / or identifying by combining with the third data.

[0034] In some embodiments, the plasma cell disorder comprises a myeloma.

[0035] In a second aspect, the present invention also provides an intelligent plasma cell disease health screening comprehensive system, characterized in that the system comprises:

[0036] The medical information receiving module is configured to receive and store medical information data, wherein the medical information data includes first data and second data; the first data includes plasma cell ratio data and / or clinically relevant data, wherein the clinically relevant data includes blood calcium level, whether bone pain exists, whether anemia exists, and urine protein level; the second data includes examination result data; the examination includes one or more of blood examination, urine examination, bone marrow examination, imaging examination, nuclear medicine examination, genetic examination, and immunology examination; the second data includes examination result data; the medical information data includes subject data from a subject;

[0037] a dynamic classification module configured to classify the dynamic management level of the subject into level one, level two, level three or level four by using a first dynamic classification mechanism; if the dynamic management level of the subject is level one, transmitting the medical information data of the subject to a data processing module;

[0038] A data processing module is configured to determine whether the number of valid indicators in the second data of the subject is qualified; if so, transmit the medical information data of the subject to the first analysis module; if not, enter the third analysis module;

[0039] A first analysis module is configured to analyze a first classification result of the subject, comprising:

[0040] The first analysis unit is configured to analyze whether there is a conflicting indicator combination in the medical information data; if so, perform a first correction to exclude the existing conflicting indicator combination, generate the first corrected medical information data and transmit it to the second analysis unit; if not, directly transmit it to the second analysis unit;

[0041] A second analysis unit is configured to analyze whether the medical information data is complete for the first classification; if so, generate a first classification result of the subject's plasma cell disease and a recommended first treatment plan, maintain the subject's dynamic management level at level one and transmit to the second analysis module; if not, transmit to the third analysis unit;

[0042] The third analysis unit is configured to analyze the acceptability of the medical information data; when it is unacceptable, directly transmit it to the second prompt information generation unit; when it is acceptable, perform a second correction on it and generate second corrected medical information data, and determine whether the index after the second correction is excluded in the first analysis unit; if so, transmit it to the second prompt information generation unit; if not, transmit it to the second analysis unit;

[0043] The second prompt information generating unit is configured to generate the inspection priority prompt information and determine whether the subject has newly entered medical data information; if so, transmit it to the first analyzing unit; if not, keep the dynamic management level of the subject at level one and transmit it to the second comprehensive management module;

[0044] The second comprehensive management module is configured to provide the classification results and recommended treatment plans for the subject based on the medical information data through medical experts, and track the actual diagnosis results and actual treatment plans received by the subject.

[0045] In some embodiments, the dynamic grading module includes:

[0046] A first judgment unit is configured to judge whether the first data satisfies a second dynamic classification mechanism; if so, enter the second judgment unit; if not, enter the third judgment unit; wherein the second dynamic classification mechanism requires that the first data satisfies a preset data type for distinguishing plasma cell diseases;

[0047] A second judgment unit is configured to determine whether the preset data type for distinguishing plasma cell disease is abnormal; if so, the dynamic management level of the subject is classified into level one and transmitted to the data processing module; if not, the dynamic management level of the subject is classified into level four;

[0048] A third judgment unit is configured to judge the number of abnormal indicators in the clinical-related data of the subject; when the number of abnormal indicators of the subject is at least three, the dynamic management level of the subject is divided into one level; when the number of abnormal indicators of the subject is two, the dynamic management level of the subject is divided into two levels; when the number of abnormal indicators of the subject is at most one, the dynamic management level of the subject is divided into three levels and enters the fourth judgment unit;

[0049] a fourth judgment unit configured to judge whether the abnormal index of the subject is the urine protein level; if so, upgrading the dynamic management level of the subject to level 2; if not, entering the first prompt information generating unit;

[0050] A first prompt information generating unit is configured to generate an inspection priority prompt information and determine whether the subject has newly entered first data; if so, enter the first dynamic adjustment unit; if not, maintain the dynamic management level of the subject at level three;

[0051] The first dynamic adjustment unit is configured to determine whether the newly entered first data contains data information that has excluded other diseases; if so, the dynamic management level of the subject is upgraded to level two; if not, the dynamic management level of the subject is maintained at level three.

[0052] In some embodiments, the system further comprises a second analysis module configured to analyze a second classification result of the subject, comprising:

[0053] a fourth analysis unit configured to analyze whether the medical information data is complete for the second classification; if so, generate a second classification result of the subject's plasma cell disease and a recommended second treatment plan, maintain the subject's dynamic management level at level one and transmit the results to the first comprehensive management module; if not, enter the third prompt information generation unit;

[0054] The third prompt information generating unit generates the inspection priority prompt information and determines whether the subject has any newly entered medical data information; if so, it is transmitted to the fourth analyzing unit; if not, the dynamic management level of the subject is maintained at level one and transmitted to the second comprehensive management module.

[0055] In some embodiments, the plasma cell disorder comprises a myeloma.

[0056] Compared with the prior art, the beneficial effects of the present invention include at least the following aspects:

[0057] Existing technologies rely more on obtaining accurate medical information from hospital information systems. However, due to the privacy of medical information, it is difficult for conventional systems to directly use data recorded in hospital information systems. In addition, existing technologies have high requirements for the completeness of the subject's medical information (especially the test result information), and are mainly aimed at subjects who have completed more plasma cell disease-related examinations. In the actual screening of plasma cell diseases, many subjects cannot be captured by the existing "high-threshold" screening systems or methods (or even excluded) due to the limited number of plasma cell disease-related examinations they have received, making it even more difficult to manage them effectively.

[0058] By setting up a first dynamic grading mechanism, a second dynamic grading mechanism and a first classification mechanism, the present invention can "low-threshold" include a wider range of target subjects into the dynamic management scope of the present invention, while carrying out clear dynamic management grading and hierarchical comprehensive management methods for the included subjects, while reducing costs and increasing efficiency. It is suitable for application scenarios such as health screening and long-term follow-up monitoring of plasma cell diseases, and can be popularized in medical institutions of different levels (especially primary medical institutions).

[0059] Medical information is private (i.e., medical information stored in the hospital information system cannot be directly used by conventional systems). The medical information data involved in the present invention is entered by the data entry personnel. In particular, when the number of target subjects included continues to increase, the problem of defects in the entered medical information data will inevitably increase. By setting up the first classification mechanism (and the second classification mechanism), the present invention is based on limited medical information data, without adding additional inspection burden to the subjects, and can accurately diagnose the plasma cell disease of the subjects in a highly fault-tolerant and defect-tolerant manner and achieve targeted comprehensive management. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] In order to more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings required for use in the embodiments or the prior art descriptions are briefly introduced below. In all the drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, each element or part is not necessarily drawn according to the actual scale. Obviously, the drawings described below are some embodiments of the present invention. For those of ordinary skill in the art, other drawings can also be obtained based on these drawings without paying creative labor.

[0061] Figure 1 is a flow chart of the method of embodiment 1;

[0062] Figure 2 This is a flow chart of S102 of Embodiment 1;

[0063] Figure 3 This is a schematic diagram of the modules of the system of Embodiment 2;

[0064] Figure 4 The figure is a roadmap of the method of embodiment 1. DETAILED DESCRIPTION

[0065] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0066] Herein, suffixes such as "module", "component" or "unit" used to represent elements are only used to facilitate the description of the present invention, and have no specific meanings by themselves. Therefore, "module", "component" or "unit" can be used mixedly.

[0067] In this document, the directions or positional relationships indicated by the terms "upper", "lower", "inner", "outer", "front", "rear", "one end", "the other end", etc. are based on the directions or positional relationships shown in the drawings, and are only for the convenience of describing the present invention and simplifying the description, and do not indicate or imply that the devices or elements referred to must have a specific direction, be constructed and operate in a specific direction, and therefore cannot be understood as limiting the present invention. In addition, the terms "first" and "second" are used for descriptive purposes only and cannot be understood as indicating or implying relative importance.

[0068] In this document, unless otherwise clearly specified and limited, the terms "installed", "provided with", "connected", etc. should be understood in a broad sense. For example, "connected" can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection, a direct connection, or an indirect connection through an intermediate medium, or it can be the internal communication of two components. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.

[0069] Herein "and / or" includes any and all combinations of one or more of the associated listed items.

[0070] Herein, "plurality" means two or more than two, ie, it includes two, three, four, five, etc.

[0071] It should be noted that, in this article, the terms "include", "comprises" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, an element defined by the sentence "comprises a ..." does not exclude the existence of other identical elements in the process, method, article or device including the element.

[0072] As used in this specification, the term "about" typically means + / - 5% of the stated value, more typically + / - 4% of the stated value, more typically + / - 3% of the stated value, more typically + / - 2% of the stated value, even more typically + / - 1% of the stated value, and even more typically + / - 0.5% of the stated value.

[0073] In this specification, some embodiments may be disclosed in a format of being in a range. It should be understood that this description of "being in a range" is only for convenience and brevity, and should not be interpreted as a rigid limitation on the disclosed range. Therefore, the description of the range should be considered to have specifically disclosed all possible sub-ranges and independent numerical values ​​within this range. For example, the description of the range 1-6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as individual numbers within this range, such as 1, 2, 3, 4, 5 and 6. Regardless of the breadth of the range, the above rules apply.

[0074] Embodiment 1

[0075] Plasma cell disease refers to a group of malignant (for example, multiple myeloma is the most common plasma cell tumor) and non-malignant diseases in which the abnormal proliferation of plasma cells is accompanied or not accompanied by the production of a large number of abnormal antibodies. The clinical manifestations of plasma cell disease vary, ranging from asymptomatic, stable state (for example, only monoclonal protein exists) to progression to tumors (such as multiple myeloma). Plasma cell disease has the characteristics of complicated laboratory tests, complex diagnosis and typing, and the combination of different examination methods is crucial for the accurate diagnosis of plasma cell disease. However, due to the constraints of medical conditions, economic conditions and other factors, it is often difficult for subjects who visit primary medical institutions to undergo a relatively complete examination at one time. In addition, even if the subjects undergo some examinations related to plasma cell disease, these examination results may be incorrect when they are entered. When the medical information data stored in the hospital information system cannot be directly used, it is difficult for existing technologies to accurately diagnose and effectively manage plasma cell disease in subjects based on the limited examination results of the subjects.

[0076] In view of the above situation, if Figure 1 and Figure 4 As shown, this embodiment provides an intelligent plasma cell disease health screening and dynamic hierarchical management method, which is characterized by comprising the following steps:

[0077] S101: Acquire medical information data of a subject, where the medical information data includes first data and second data;

[0078] In some embodiments, the first data includes plasma cell ratio data and / or clinically relevant data. In some embodiments, the clinically relevant data includes blood calcium level, bone pain, anemia and urine protein level.

[0079] In some embodiments, the plasma cell proportion data is obtained by counting bone marrow cell smears and / or biopsy methods.

[0080] In some embodiments, the second data includes inspection result data.

[0081] In some embodiments, the test includes one or more of a blood test, a urine test, a bone marrow test, an imaging test, a nuclear medicine test, a genetic test, and an immunological test.

[0082] In some embodiments, the second data may include one or more of hemoglobin level, creatinine level, bone X-ray examination, IgG level, IgA level, urine Bencenic protein level, β2 microglobulin level, lactate dehydrogenase level and fluorescence in situ hybridization examination.

[0083] It should be understood that the data types of the first data and the second data do not overlap.

[0084] S102: Based on the first data, a first dynamic classification mechanism (see Figure 4 ), classifying the dynamic management level of the subject into level one, level two, level three or level four; if the dynamic management level of the subject is level one, proceeding to S103;

[0085] Among them, Figure 2 As shown, S102 includes:

[0086] S11: Determine whether the first data satisfies a second dynamic classification mechanism; if yes, proceed to S12; if no, proceed to S13; wherein the second dynamic classification mechanism requires that the first data satisfies a preset data type for distinguishing plasma cell diseases;

[0087] In some embodiments, the preset data type for distinguishing plasma cell diseases may be only plasma cell ratio data.

[0088] In some embodiments, the preset data type for distinguishing plasma cell diseases may also be a combination of plasma cell ratio data and clinically relevant data, such as any one of the clinically relevant data.

[0089] It should be noted that, by setting up a second dynamic grading mechanism, this embodiment can, on the one hand, distinguish healthy subjects from subjects with potential plasma cell diseases (referred to as "target subjects"), thereby enabling this embodiment to more specifically dynamically manage target subjects (e.g., subjects with a dynamic management level of one, two, or three). On the other hand, considering that the actual examination items for subjects visiting primary medical institutions are relatively limited, when the method provided in this embodiment is applied to perform a health screening on subjects, the preset data type for distinguishing plasma cell diseases can be dynamically adjusted according to the actual screening situation, so as to include target subjects (e.g., subjects with a greater risk of developing plasma cell diseases) within the dynamic management scope of this embodiment.

[0090] S12: determining whether the preset data type for distinguishing plasma cell disease in the first data is abnormal; if so, classifying the dynamic management level of the subject into level one and proceeding to S103; if not, classifying the dynamic management level of the subject into level four;

[0091] In some embodiments, whether a certain data of the subject is abnormal can be determined by comparing it with a reference standard (or normal level). Taking the plasma cell ratio as an example, when the plasma cell ratio of the subject is greater than the reference standard (e.g., 10%), the plasma cell ratio data of the subject is considered abnormal.

[0092] S13: Determine the number of abnormal indicators in the clinically relevant data; when the number of the abnormal indicators is at least three, classify the dynamic management level of the subject into level one and proceed to S103; when the number of the abnormal indicators is two, classify the dynamic management level of the subject into level two and proceed to S201; when the number of the abnormal indicators of the subject is at most one, classify the dynamic management level of the subject into level three and proceed to S14;

[0093] S14: Determine whether the abnormal indicator of the subject is the urine protein level; if so, upgrade the dynamic management level of the subject to level 2 and proceed to S201; if not, proceed to S15;

[0094] S15: Generate inspection priority prompt information and determine whether the subject has newly entered first data; if so, proceed to S16; if not, maintain the dynamic management level of the subject at level three;

[0095] Although the above-mentioned second dynamic grading mechanism can distinguish healthy subjects from subjects with potential plasma cell diseases, the subjects may not have undergone examinations such as plasma cell ratio examinations. That is to say, in the actual screening of plasma cell diseases, many target subjects cannot be captured by the existing "high threshold" screening system or method (or even excluded) due to the limited examinations related to plasma cell diseases, so it is even more difficult to manage them effectively. By setting up the first dynamic grading mechanism, this embodiment can include a wider range of target subjects in the dynamic management scope of this embodiment, avoiding the situation of missed screening to a certain extent. Although this embodiment includes a wider range of target subjects, because this embodiment has a clear dynamic management classification and hierarchical comprehensive management method for the included subjects, the included subjects can be managed in a targeted manner and tracked for a long time to promote early detection, early treatment and disease progression monitoring of plasma cell diseases.

[0096] In some embodiments, the examination priority prompt information includes that the first examination recommendation priority is urine protein level examination, the second examination recommendation priority is plasma cell ratio examination, and the third examination recommendation priority is to go to the corresponding department for treatment to rule out other diseases with the same or similar symptoms.

[0097] Based on the first data entered by the subject, this embodiment generates targeted inspection priority prompt information to avoid the subject from receiving more additional inspections as much as possible, while prompting the target subject to undergo the first classification and obtain more targeted comprehensive management. In addition, this embodiment focuses on evaluating the urine protein level of the subject, which is not only more popular (both physical examination centers and primary medical institutions can test it), but also can play a better "early warning" role, so as to include more target subjects in the dynamic management scope of this embodiment.

[0098] S16: Determine whether the newly entered first data contains data information that has excluded other diseases; if so, upgrade the dynamic management level of the subject to level two; if not, maintain the dynamic management level of the subject at level three.

[0099] This embodiment will determine whether the newly entered first data contains data information that has excluded other diseases as the "bottom line" of the first dynamic classification mechanism, so as to appropriately classify the dynamic management level of the subject. In summary, this embodiment can not only include a wider range of target subjects into the dynamic management scope of this embodiment, but also provide a clear dynamic management level and hierarchical comprehensive management of the subjects based on limited medical information data (such as the first data) without adding additional examination burden to the subjects.

[0100] The diagnosis and classification of plasma cell diseases are complex, and accurate diagnosis is crucial to the treatment of subjects, as well as prognosis assessment and risk stratification. Taking into account the privacy of medical information (i.e., medical information stored in the hospital information system cannot be directly used by conventional systems), the medical information data involved in this embodiment is entered by the data entry person. In some embodiments, the data entry person includes subjects, medical staff and / or other personnel. In other words, the entered medical information data may be accurate or may be flawed, such as incorrect filling or missing filling. In particular, as the number of target subjects included continues to increase, the problem of defects in medical information data will inevitably increase. In response to this situation:

[0101] S103 uses the first classification mechanism to determine whether the number of valid indicators of the second data of the subject is qualified (see Figure 4 If yes, then go to S104; if no, then go to S106;

[0102] In the present invention, "effective index" refers to data with clear results of a certain examination involved in the second data, and there is only one effective index for a test. Accordingly, when the subject has not undergone a certain examination involved in the second data, the examination does not have a clear result and cannot be regarded as an effective index. Taking the test result of hemoglobin as an example, ">100 g / L" or "<85 g / L" can be regarded as an effective indicator, while "not undergoing the examination" cannot be regarded as a valid indicator.

[0103] It should be understood that the specific effective index quantity qualification rule can be set by oneself. In some embodiments, it can be determined whether the effective index quantity of the subject is qualified by comparing it with the effective index quantity qualification threshold.

[0104] In some embodiments, the qualifying threshold for the number of valid indicators may be 1, 2, 3, 4 or 5.

[0105] The confirmation of the effective indicators in the second data is very important for the diagnosis and typing / staging of plasma cell diseases. Taking into account factors such as medical conditions and economic conditions, this embodiment actually allows the number of effective indicators in the second data of the subject to be entered to be 0, that is, the subject has not received any examination corresponding to the second data. This can improve the acceptance of the data entry person to a certain extent, and facilitate the data entry person to enter the medical information data of the subject to adapt to a wider range of target subjects. Of course, even if the number of effective indicators of the subject is unqualified, this embodiment can also effectively manage it dynamically.

[0106] In view of the situation that the examinations received by the subject may be relatively limited and the entered second data may be flawed, this embodiment first analyzes whether there is a conflicting indicator combination in the medical information data (including the first data and the second data);

[0107] S104 Analyze whether there is a conflicting indicator combination in the medical information data; if so, perform a first correction to exclude the conflicting indicator combination in the medical information data, generate a first corrected medical information data and enter S105; if not, directly enter S105.

[0108] In the present invention, a conflicting indicator combination refers to contradictory indicators in medical information data, and the contradictory indicators are sufficient to affect the classification results. For example, when the subject's urine Bencenic protein level is abnormal, the urine protein level is almost impossible to be normal. At this time, the abnormal urine Bencenic protein level and the normal urine protein level are a conflicting indicator combination.

[0109] S105 analyzes whether the medical information data is complete for the first classification; if so, generates a first classification result of the subject's plasma cell disease and a recommended first treatment plan, maintains the subject's dynamic management level at level one and proceeds to S108; if not, proceeds to S106.

[0110] In the present invention, complete means that the medical information data is sufficient to classify the subject into a specific plasma cell disorder (first classification) and / or a stratification / stage of a plasma cell disorder (second classification).

[0111] In some embodiments, the plasma cell disorder includes reactive plasmacytosis, monoclonal gammopathy of undetermined significance, clinically significant monoclonal gammopathy, plasmacytoma, multiple myeloma, macroglobulinemia, amyloidosis, heavy chain disease, or monoclonal light and heavy chain deposition disease, etc.

[0112] Through the above steps, subjects with complete medical data information for the first classification can be accurately classified into the first classification. However, there are still cases where the medical data information is incomplete (for example, it is difficult to diagnose the subject due to lack of systematic examinations excluded by the first correction). For this, this embodiment analyzes the acceptability of the medical information data.

[0113] S106 analyzes the acceptability of the medical information data; when it is unacceptable, directly enters S107; when it is acceptable, it is second-corrected and generates second-corrected medical information data, and determines whether the indicators after the second correction are excluded in S104; if so, enters S107; if not, returns to S105.

[0114] In some embodiments, the acceptability refers to whether the difference between the incomplete medical data information of the subject and the closest complete medical data information is within the acceptable range of the first classification. If it is acceptable (for example, the medical data information of the subject differs from the closest complete medical data information by only one data item), the medical information data of the subject is subjected to a second correction. In other words, even if the medical data information of the subject is relatively incomplete, the present embodiment can perform the first classification of the subject without the need for additional supplementary examinations. In order to ensure the accuracy of the first classification of the subject, for subjects with large differences or whose indicators have been excluded by S104 after the second correction, the present embodiment generates targeted examination priority prompt information, suggesting that the subject supplement the necessary examination result information (for example, as few or as highly feasible examination results as possible) to promote the first classification of the target subject.

[0115] S107 generates inspection priority prompt information and determines whether the subject has newly entered medical data information; if so, returns to S104; if not, maintains the dynamic management level of the subject at level one and performs second comprehensive management.

[0116] In some embodiments, the examination priority prompt information includes a first examination suggestion priority for examination result information that should at least be supplemented; a second examination suggestion priority for replaceable examination result information that should at least be supplemented; and a third examination suggestion priority for examination result information that can be performed by the medical institution where the subject is treated.

[0117] In addition, it should be noted that this embodiment does not exclude subjects with incomplete medical data information (for example, subjects who cannot supplement the examination results even with the prompt information) from the scope of dynamic management. For subjects with a first-level dynamic management level but incomplete medical data information of the first classification, this embodiment performs a second comprehensive management on them. Without the subject undergoing additional supplementary examinations, medical experts provide the subject with classification results and recommended treatment plans based on the medical information data to promote early detection and treatment of plasma cell diseases.

[0118] In some embodiments, the second comprehensive management method includes: providing a classification result and a recommended treatment plan for the subject based on the medical information data by a medical expert, and tracking the actual diagnosis result and the actual treatment plan received by the subject.

[0119] In some embodiments, after the actual diagnosis result and the actual treatment plan received by the subject are entered, the dynamic management level of the subject is maintained at level one and the subject is subjected to the first comprehensive management.

[0120] In some embodiments, it also includes:

[0121] S108 uses the second classification mechanism to analyze whether the medical information data is complete for the second classification (see Figure 4 If so, generate a second classification result of the subject's plasma cell disease and a recommended second treatment plan, maintain the subject's dynamic management level at level one and perform the first comprehensive management (see Figure 4 "First Comprehensive Management" section); if not, proceed to S109;

[0122] S109 Generate inspection priority prompt information and determine whether the subject has newly entered medical data information; if so, return to S108; if not, maintain the dynamic management level of the subject at level one and perform the second comprehensive management (see Figure 4 of the “Second Integrated Management” section).

[0123] For subjects whose dynamic management level is level one and whose medical data information of the first classification is complete, this embodiment performs a second classification on them to further classify / stage their plasma cell disease, and based on the second classification results, outputs a more accurate recommended second treatment plan to better provide treatment recommendations for the subjects.

[0124] Considering that if the subject expects to receive treatment, he still needs to go to a medical institution for treatment, so as to obtain the actual diagnosis result and the actual treatment plan received. On the one hand, the first classification result and / or the second classification result of this embodiment can be used as an auxiliary electronic medical record to improve the doctor's diagnosis and treatment efficiency and medical quality. On the other hand, limited by the doctor's subjective factors and the difficulty of diagnosing plasma cell diseases, the subject's actual diagnosis result and / or the actual treatment plan received may not be accurate and appropriate. For subjects with a dynamic management level of one and who obtain the second classification result, this embodiment performs the first comprehensive management on them:

[0125] In some embodiments, the first integrated management method comprises: obtaining the actual diagnosis result of the subject and comparing the first and second classification results of the subject with the actual diagnosis result; and / or

[0126] Obtaining the treatment regimen actually received by the subject and its efficacy and comparing it with the first and second recommended treatment regimens;

[0127] When the comparison results are consistent, the first comprehensive management is maintained; when the comparison results are inconsistent, the subject is subjected to the second comprehensive management.

[0128] In some embodiments, if the dynamic management level of the subject is level 2, the following steps are performed:

[0129] S201: using the first classification mechanism, analyzing whether the medical information data is complete for the first classification; if so, upgrading the dynamic management level of the subject to level one and proceeding to S105; if not, proceeding to S202;

[0130] S202 Generate inspection priority prompt information and determine whether the subject has newly entered medical data information; if so, return to S201; if not, maintain the dynamic management level of the subject at level 2 and perform level 3 comprehensive management (see Figure 4 of the “Third Integrated Management” section).

[0131] In some embodiments, if the dynamic management level of the subject is level three, the following steps are performed:

[0132] S301: using the first classification mechanism, analyzing whether the medical information data is complete for the first classification; if so, upgrading the dynamic management level of the subject to level one and proceeding to S105; if not, proceeding to S302;

[0133] S302 generates inspection priority prompt information and determines whether the subject has newly entered medical data information; if so, returns to S301; if not, maintains the dynamic management level of the subject at level three and performs the third comprehensive management (see Figure 4 of the “Third Integrated Management” section).

[0134] Similarly, for subjects with a dynamic management level of level 2 or 3, this embodiment prompts them to undergo the first classification and dynamically adjusts their dynamic management level to provide more targeted comprehensive management. For subjects with a lower dynamic management level and who are difficult to accept additional examinations, this embodiment performs the third comprehensive management on them to monitor the development trend of their plasma cell disease:

[0135] In some embodiments, the third comprehensive management method includes monitoring the development trend of the plasma cell disease of the subject; if there is a worsening development trend, the dynamic management level of the subject is upgraded (for example, the subject with a dynamic management level of level three is upgraded to level two, and the subject with a dynamic management level of level two is upgraded to level one); if there is no worsening development trend, the dynamic management level of the subject is maintained at the original level.

[0136] In some embodiments, the method for monitoring the development trend of the subject's plasma cell disease includes: identifying whether the first data and / or the second data produce an abnormal trend, and / or combining with the third data. Taking anemia as an example, if the subject's anemia has an increasing trend, the subject's plasma cell disease may have a worsening development trend.

[0137] In some embodiments, the third data includes clinical baseline data, such as risk factors for plasma cell disorders.

[0138] In some embodiments, the third data may include one or more of family history of plasma cell disease, gender, age, height, weight, BMI, diastolic blood pressure, systolic blood pressure, blood sugar, smoking history, and drinking history.

[0139] In some embodiments, if the dynamic management level of the subject is level four, a third comprehensive management may also be performed on the subject.

[0140] Embodiment 2

[0141] like Figure 3 As shown, this embodiment provides an intelligent plasma cell disease health screening integrated system 100 corresponding to the method of embodiment 1, which includes:

[0142] The medical information receiving module 102 is configured to receive and store medical information data, wherein the medical information data includes first data and second data;

[0143] In some embodiments, the first data includes plasma cell ratio data and / or clinically relevant data. In some embodiments, the clinically relevant data includes blood calcium level, bone pain, anemia and urine protein level.

[0144] In some embodiments, the second data includes inspection result data.

[0145] In some embodiments, the test includes one or more of a blood test, a urine test, a bone marrow test, an imaging test, a nuclear medicine test, a genetic test, and an immunological test.

[0146] In some embodiments, the second data may include one or more of hemoglobin level, creatinine level, bone X-ray examination, IgG level, IgA level, urine Bencenic protein level, β2 microglobulin level, lactate dehydrogenase level and fluorescence in situ hybridization examination.

[0147] It should be understood that the data types of the first data and the second data do not overlap.

[0148] In some embodiments, the medical information data also includes third data.

[0149] In some embodiments, the third data comprises clinical baseline data.

[0150] In some embodiments, the third data may include one or more of family history of plasma cell disease, gender, age, height, weight, BMI, diastolic blood pressure, systolic blood pressure, blood sugar, smoking history, and drinking history.

[0151] In some embodiments, the medical information data includes subject data from a subject.

[0152] The dynamic classification module 104 is configured to use a first dynamic classification mechanism to classify the dynamic management level of the subject into level one, level two, level three or level four; if the dynamic management level of the subject is level one, the medical information data of the subject is transmitted to the data processing module 106;

[0153] The dynamic classification module 104 includes:

[0154] The first judgment unit 202 is configured to judge whether the first data satisfies the second dynamic classification mechanism; if so, it proceeds to the second judgment unit 204; if not, it proceeds to the third judgment unit 206;

[0155] The second dynamic classification mechanism requires that the first data meets a preset data type for distinguishing plasma cell diseases.

[0156] In some embodiments, the preset data type for distinguishing plasma cell diseases may be only plasma cell ratio data.

[0157] In some embodiments, the preset data type for distinguishing plasma cell diseases may also be a combination of plasma cell ratio data and clinically relevant data, such as any one of the clinically relevant data.

[0158] The second judgment unit 204 is configured to judge whether the preset data type for distinguishing plasma cell disease in the first data is abnormal; if so, the dynamic management level of the subject is classified into level one and transmitted to the data processing module 106; if not, the dynamic management level of the subject is classified into level four;

[0159] The third judgment unit 206 is configured to judge the number of abnormal indicators in the clinical-related data of the subject; when the number of abnormal indicators of the subject is at least three, the dynamic management level of the subject is divided into one level and transmitted to the data processing module 106; when the number of abnormal indicators of the subject is two, the dynamic management level of the subject is divided into two levels and transmitted to the second analysis module 108; when the number of abnormal indicators of the subject is at most one, the dynamic management level of the subject is divided into three levels and enters the fourth judgment unit 208;

[0160] The fourth judgment unit 208 is configured to judge whether the abnormal index of the subject is the urine protein level; if so, the dynamic management level of the subject is upgraded to level 2 and transmitted to the second analysis module 108; if not, enter the first prompt information generation unit 210;

[0161] The first prompt information generating unit 210 is configured to generate the inspection priority prompt information and determine whether the subject has newly entered first data; if so, enter the first dynamic adjustment unit 212; if not, maintain the dynamic management level of the subject at level three;

[0162] In some embodiments, the examination priority prompt information includes that the first examination recommendation priority is urine protein concentration examination, the second examination recommendation priority is plasma cell ratio examination, and the third examination recommendation priority is to go to the corresponding department for treatment to rule out other diseases with the same or similar symptoms.

[0163] The first dynamic adjustment unit 212 is configured to determine whether the newly entered first data contains data information that has excluded other diseases; if so, the dynamic management level of the subject is upgraded to level two; if not, the dynamic management level of the subject is maintained at level three.

[0164] The data processing module 106 is configured to determine whether the number of valid indicators in the second data of the subject is qualified; if so, the medical information data of the subject is transmitted to the first analysis module 108; if not, the third analysis module 112 is entered;

[0165] In some embodiments, the first analysis module 108 is configured to analyze the first classification result of the subject, which includes:

[0166] The first analysis unit 302 is configured to analyze whether there is a conflicting indicator combination in the medical information data; if so, perform a first correction to exclude the existing conflicting indicator combination, generate a first corrected medical information data and enter the second analysis unit 304; if not, directly enter the second analysis unit 304.

[0167] The second analysis unit 304 is configured to analyze whether the medical information data is complete for the first classification; if so, generate a first classification result of the subject's plasma cell disease and a recommended first treatment plan, maintain the subject's dynamic management level at level one and transmit it to the second analysis module 110; if not, enter the third analysis unit 306.

[0168] The third analysis unit 306 is configured to analyze the acceptability of the medical information data; when it is unacceptable, it is directly transmitted to the second prompt information generation unit 308; when it is acceptable, it is second-corrected and generates second-corrected medical information data, and determines whether the second-corrected indicator is excluded in the first analysis unit 302; if so, it is transmitted to the second prompt information generation unit 308; if not, it is transmitted to the second analysis unit 304;

[0169] The second prompt information generating unit 308 is configured to generate the examination priority prompt information and determine whether the subject has newly entered medical data information; if so, transmit it to the first analyzing unit 302; if not, keep the dynamic management level of the subject at level one and transmit it to the second comprehensive management module 404;

[0170] In some embodiments, the examination priority prompt information includes a first examination suggestion priority for examination result information that should at least be supplemented; a second examination suggestion priority for replaceable examination result information that should at least be supplemented; and a third examination suggestion priority for examination result information that can be performed by the medical institution where the subject is treated.

[0171] The second comprehensive management module 404 is configured to provide the classification results and recommended treatment plans for the subject based on the medical information data through medical experts, and track the actual diagnosis results and actual treatment plans received by the subject.

[0172] In some embodiments, the second integrated management module 404 is further configured to maintain the dynamic management level of the subject at level one and transmit it to the first integrated management module 402 after the actual diagnosis result and the actual treatment plan received by the subject are entered.

[0173] In some embodiments, the method further includes a second analysis module 110 configured to analyze a second classification result of the subject, which includes:

[0174] The fourth analysis unit 310 is configured to analyze whether the medical information data is complete for the second classification; if so, generate a second classification result of the subject's plasma cell disease and a recommended second treatment plan, maintain the dynamic management level of the subject at level one and transmit it to the first comprehensive management module 402; if not, enter the third prompt information generation unit 312;

[0175] The third prompt information generating unit 312 is configured to generate examination priority prompt information and determine whether the subject has newly entered medical data information; if so, it is transmitted to the fourth analyzing unit 310; if not, the dynamic management level of the subject is maintained at level one and transmitted to the second comprehensive management module 404.

[0176] A first integrated management module 402 is configured to obtain an actual diagnosis result of the subject and compare the first classification result and the second classification result of the subject with the actual diagnosis result; and / or

[0177] Obtaining the treatment regimen actually received by the subject and its efficacy and comparing it with the recommended first treatment regimen and second treatment regimen;

[0178] When the comparison result is consistent, the medical data information of the subject is retained in the first integrated management module; when the comparison result is inconsistent, the medical data information of the subject is transmitted to the second integrated management module 404.

[0179] In some embodiments, a third analysis module 112 is further included, which is configured to manage subjects with a dynamic management level of level 2, including:

[0180] The fifth analyzing unit 314 is configured to analyze whether the medical information data is complete for the first classification; if so, the dynamic management level of the subject is upgraded to level one and enter the first analyzing module 108; if not, enter the third prompt information generating unit 316;

[0181] The third prompt information generating unit 316 is configured to generate examination priority prompt information and determine whether the subject has newly entered medical data information; if so, it is transmitted to the fifth analysis unit 314; if not, the dynamic management level of the subject is maintained at level two and transmitted to the third comprehensive management module 406.

[0182] The third integrated management module 406 is configured to monitor the development trend of the plasma cell disease of the subject; if there is a worsening development trend, the dynamic management level of the subject is upgraded; if there is no worsening development trend, the dynamic management level of the subject is maintained at the original level.

[0183] In some embodiments, the method for monitoring the development trend of the plasma cell disorder in the subject comprises: determining whether the first data and / or the second data produce an abnormal trend, and / or identifying in combination with the third data.

[0184] In some embodiments, a fourth analysis module 114 is further included, which is configured to manage subjects with a dynamic management level of level 3, including:

[0185] The sixth analysis unit 318 is configured to analyze whether the medical information data is complete for the first classification; if so, the dynamic management level of the subject is upgraded to level one and enter the first analysis module 108; if not, enter the fourth prompt information generation unit 320;

[0186] The fourth prompt information generation unit 320 is configured to generate examination priority prompt information and determine whether the subject has newly entered medical data information; if so, it is transmitted to the sixth analysis unit 318; if not, the dynamic management level of the subject is maintained at level three and transmitted to the third comprehensive management module 406.

[0187] In some embodiments, it also includes: an update module 116, which is configured to update one or more modules (such as a dynamic grading module, a data processing module, a first analysis module, a second analysis module, a third analysis module, a first comprehensive management module, a second comprehensive management module, and a third comprehensive management module) in the intelligent plasma cell disease comprehensive health screening system 100 to meet the research status and diagnosis and treatment standards of plasma cell diseases.

[0188] In some embodiments, one or more modules in the intelligent plasma cell disease comprehensive health screening system 100 can be configured to be implemented based on a trained artificial intelligence or machine learning model.

[0189] Through the description of the above implementation methods, those skilled in the art can clearly understand that the above-mentioned embodiment methods can be implemented by means of software plus a necessary general hardware platform, and of course by hardware, but in many cases the former is a better implementation method. Based on such an understanding, the technical solution of the present invention, in essence, or the part that contributes to the prior art, can be embodied in the form of a software product, which is stored in a storage medium (such as ROM / RAM, a magnetic disk, or an optical disk), and includes a number of instructions for a computer terminal (which can be a mobile phone, a computer, a server, or a network device, etc.) to execute the methods described in each embodiment of the present invention.

[0190] The embodiments of the present invention are described above in conjunction with the accompanying drawings, but the present invention is not limited to the above-mentioned specific implementation methods. The above-mentioned specific implementation methods are merely illustrative and not restrictive. Under the enlightenment of the present invention, ordinary technicians in this field can also make many forms without departing from the scope of protection of the purpose of the present invention and the claims, which all fall within the protection of the present invention.

Claims

1. An intelligent plasma cell disease health screening and dynamic stratification management method, characterized in that: The following steps are involved: S101 Obtaining medical information data of a subject, the medical information data including first data and second data; the first data including plasma cell ratio data and / or clinically relevant data, the clinically relevant data including blood calcium level, bone pain, anemia and urine protein level; the second data including examination result data; the examination including one or more of blood examination, urine examination, bone marrow examination, imaging examination, nuclear medicine examination, genetic examination and immunological examination; S102, based on the first data, using a first dynamic classification mechanism, classifying the dynamic management level of the subject into level one, level two, level three or level four; if the dynamic management level of the subject is level one, proceeding to S103; S103: using the first classification mechanism to determine whether the number of valid indicators of the second data is qualified; if so, proceed to S104; if not, proceed to S106; S104: Analyze whether there is a conflicting indicator combination in the medical information data; if so, perform a first correction to exclude the conflicting indicator combination in the medical information data, generate the first corrected medical information data and enter S105; if not, directly enter S105; S105: analyzing whether the medical information data is complete for the first classification; if so, generating a first classification result of the subject's plasma cell disease and a recommended first treatment plan, maintaining the subject's dynamic management level at level one and proceeding to S108; if not, proceeding to S106; S106: Analyze the acceptability of the medical information data; if it is unacceptable, directly enter S107; if it is acceptable, perform a second correction on it and generate second corrected medical information data, and determine whether the index after the second correction is excluded in S104; if so, enter S107; if not, return to S105; S107 generates inspection priority prompt information and determines whether the subject has newly entered medical data information; if so, returns to S104; if not, maintains the dynamic management level of the subject at level one and performs second comprehensive management; The second comprehensive management method includes: having medical experts provide classification results and recommended treatment plans for the subject based on the medical information data, and tracking the actual diagnosis results and treatment plans actually accepted by the subject.

2. The method according to claim 1, characterized in that S102 includes: S11: Determine whether the first data satisfies a second dynamic classification mechanism; if yes, proceed to S12; if no, proceed to S13; wherein the second dynamic classification mechanism requires that the first data satisfies a preset data type for distinguishing plasma cell diseases; S12: determining whether the preset data type for distinguishing plasma cell disease in the first data is abnormal; if so, classifying the dynamic management level of the subject into level one and proceeding to S103; if not, classifying the dynamic management level of the subject into level four; S13: Determine the number of abnormal indicators in the clinical-related data; when the number of the abnormal indicators is at least three, classify the dynamic management level of the subject into level one; when the number of the abnormal indicators is two, classify the dynamic management level of the subject into level two; when the number of the abnormal indicators of the subject is at most one, classify the dynamic management level of the subject into level three and proceed to S14; S14: determining whether the abnormal indicator of the subject is the urine protein level; if so, upgrading the dynamic management level of the subject to level 2; if not, proceeding to S15; S15: Generate inspection priority prompt information and determine whether the subject has newly entered first data; if so, proceed to S16; if not, maintain the dynamic management level of the subject at level three; S16: Determine whether the newly entered first data contains data information that has excluded other diseases; if so, upgrade the dynamic management level of the subject to level two; if not, maintain the dynamic management level of the subject at level three.

3. The method according to claim 1, characterized in that The method further comprises: S108: using the second classification mechanism, analyzing whether the medical information data is complete for the second classification; if so, generating a second classification result of the subject's plasma cell disease and a recommended second treatment plan, maintaining the subject's dynamic management level at level one and performing the first comprehensive management; if not, proceeding to S109; S109 Generate inspection priority prompt information and determine whether the subject has newly entered medical data information; if so, return to S108; if not, maintain the dynamic management level of the subject at level one and perform second comprehensive management.

4. The method according to claim 3, characterized in that The first comprehensive management method comprises: obtaining the actual diagnosis result of the subject and comparing the first classification result and the second classification result of the subject with the actual diagnosis result; and / or Obtaining the treatment regimen actually received by the subject and its efficacy and comparing it with the recommended second treatment regimen; When the comparison results are consistent, the first comprehensive management is maintained; when the comparison results are inconsistent, the subject is subjected to the second comprehensive management.

5. The method according to claim 1, characterized in that If the dynamic management level of the subject is level 2, perform the following steps: S201: using the first classification mechanism, analyzing whether the medical information data is complete for the first classification; if so, upgrading the dynamic management level of the subject to level one and proceeding to S105; if not, proceeding to S202; S202 Generate inspection priority prompt information and determine whether the subject has newly entered medical data information; if so, return to S201; if not, maintain the dynamic management level of the subject at level two and perform level three comprehensive management.

6. The method according to claim 5, characterized in that The third comprehensive management method includes monitoring the development trend of the plasma cell disease of the subject; if there is a worsening development trend, upgrading the dynamic management level of the subject; if there is no worsening development trend, maintaining the dynamic management level of the subject at the original level.

7. The method according to claim 6, characterized in that The method for analyzing the development trend of the plasma cell disease of the subject includes: identifying whether the first data and / or the second data produce an abnormal trend, and / or combining with the third data.

8. The method according to claim 1, characterized in that The plasma cell disorders include myeloma.

9. An intelligent plasma cell disease health screening integrated system, characterized in that: The system comprises: The medical information receiving module is configured to receive and store medical information data, wherein the medical information data includes first data and second data; the first data includes plasma cell ratio data and / or clinically relevant data, wherein the clinically relevant data includes blood calcium level, whether bone pain exists, whether anemia exists, and urine protein level; the second data includes examination result data; the examination includes one or more of blood examination, urine examination, bone marrow examination, imaging examination, nuclear medicine examination, genetic examination, and immunology examination; the second data includes examination result data; the medical information data includes subject data from a subject; a dynamic classification module configured to classify the dynamic management level of the subject into level one, level two, level three or level four by using a first dynamic classification mechanism; if the dynamic management level of the subject is level one, transmitting the medical information data of the subject to a data processing module; A data processing module is configured to determine whether the number of valid indicators in the second data of the subject is qualified; if so, transmit the medical information data of the subject to the first analysis module; if not, enter the third analysis module; A first analysis module is configured to analyze a first classification result of the subject, comprising: The first analysis unit is configured to analyze whether there is a conflicting indicator combination in the medical information data; if so, perform a first correction to exclude the existing conflicting indicator combination, generate the first corrected medical information data and transmit it to the second analysis unit; if not, directly transmit it to the second analysis unit; A second analysis unit is configured to analyze whether the medical information data is complete for the first classification; if so, generate a first classification result of the subject's plasma cell disease and a recommended first treatment plan, maintain the subject's dynamic management level at level one and transmit to the second analysis module; if not, transmit to the third analysis unit; The third analysis unit is configured to analyze the acceptability of the medical information data; when it is unacceptable, directly transmit it to the second prompt information generation unit; when it is acceptable, perform a second correction on it and generate second corrected medical information data, and determine whether the index after the second correction is excluded in the first analysis unit; if so, transmit it to the second prompt information generation unit; if not, transmit it to the second analysis unit; The second prompt information generating unit is configured to generate the inspection priority prompt information and determine whether the subject has newly entered medical data information; if so, transmit it to the first analyzing unit; if not, keep the dynamic management level of the subject at level one and transmit it to the second comprehensive management module; The second comprehensive management module is configured to provide the classification results and recommended treatment plans for the subject based on the medical information data through medical experts, and track the actual diagnosis results and actual treatment plans received by the subject.

10. The system according to claim 9, characterized in that The dynamic classification module includes: A first judgment unit is configured to judge whether the first data satisfies a second dynamic classification mechanism; if so, enter the second judgment unit; if not, enter the third judgment unit; wherein the second dynamic classification mechanism requires that the first data satisfies a preset data type for distinguishing plasma cell diseases; A second judgment unit is configured to determine whether the preset data type for distinguishing plasma cell disease is abnormal; if so, the dynamic management level of the subject is classified into level one and transmitted to the data processing module; if not, the dynamic management level of the subject is classified into level four; A third judgment unit is configured to judge the number of abnormal indicators in the clinical-related data of the subject; when the number of abnormal indicators of the subject is at least three, the dynamic management level of the subject is divided into one level; when the number of abnormal indicators of the subject is two, the dynamic management level of the subject is divided into two levels; when the number of abnormal indicators of the subject is at most one, the dynamic management level of the subject is divided into three levels and enters the fourth judgment unit; a fourth judgment unit configured to judge whether the abnormal index of the subject is the urine protein level; if so, upgrading the dynamic management level of the subject to level 2; if not, entering the first prompt information generating unit; A first prompt information generating unit is configured to generate an inspection priority prompt information and determine whether the subject has newly entered first data; if so, enter the first dynamic adjustment unit; if not, maintain the dynamic management level of the subject at level three; The first dynamic adjustment unit is configured to determine whether the newly entered first data contains data information that has excluded other diseases; if so, the dynamic management level of the subject is upgraded to level two; if not, the dynamic management level of the subject is maintained at level three.

11. The system according to claim 9, characterized in that The system further comprises a second analysis module configured to analyze a second classification result of the subject, comprising: a fourth analysis unit configured to analyze whether the medical information data is complete for the second classification; if so, generate a second classification result of the subject's plasma cell disease and a recommended second treatment plan, maintain the subject's dynamic management level at level one and transmit the results to the first comprehensive management module; if not, enter the third prompt information generation unit; The third prompt information generating unit generates the inspection priority prompt information and determines whether the subject has any newly entered medical data information; if so, it is transmitted to the fourth analyzing unit; if not, the dynamic management level of the subject is maintained at level one and transmitted to the second comprehensive management module.

12. The system according to claim 9, characterized in that The plasma cell disorders include myeloma.

Images